MDGL | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.81%

1 Month

17.86%

3 Months

5.95%

6 Months

26.86%

1 Year

74.32%

2 Year

147.17%

Key data

Stock price

$527.69

P/E Ratio

0.00

DAY RANGE

$516.44 - $534.39

EPS

-$12.85

52 WEEK RANGE

$265.00 - $615.00

52 WEEK CHANGE

$70.89

MARKET CAP

13.226 B

YIELD

N/A

SHARES OUTSTANDING

22.940 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-06-2025

BETA

0.68

PUBLIC FLOAT

AVERAGE 10 VOLUME

$277,569

AVERAGE 30 VOLUME

$369,619

Company detail

CEO: Paul A. Friedman
Region: US
Website: madrigalpharma.com
Employees: 90
IPO year: 2007

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.

MDGL - MADRIGAL PHARMACEUTICALS, INC.